-
The market of more than 10 billion anti-AIDS drugs has attracted pharmaceutical companies to layout, and another domestic class 1 new drug is launched in the new year!
Time of Update: 2023-02-03
Another domestic anti-AIDS class 1 new drug was launched On January 5, Addi Pharmaceutical announced that the company's research and development of enomiti tablets (trade name: Fubond) was approved for marketing.
-
Accelerate the layout of diabetes, and strive for the research and development of new anti-aging drugs... At the beginning of the new year of 2023, pharmaceutical companies are busy with financing
Time of Update: 2023-02-03
Sihuan Pharmaceutical recently announced that Huisheng Biotechnology, a non-wholly-owned subsidiary of the Group, has successfully completed the Series A+ financing conducted by Jilin Baixing Bai Rong Investment Center (Limited Partnership), Jilin Equity Fund Investment Co.
-
Improving innovation capabilities has become a general trend in the industry, and pharmaceutical equipment companies will continue to increase investment in research and development in the future
Time of Update: 2023-02-03
In the future, pharmaceutical equipment companies will continue to increase investment in research and development (Image source: Pharmaceutical Network) It is reported that in China, the head pharmaceutical machine companies represented by Chutian Technology and Dongfulong have been continuously increasing investment in research and development, constantly enriching product categories, optimizing product structure, actively deploying new tracks such as biopharmaceuticals and vaccines, and continuously meeting the downstream localization replacement needs while promoting the high-quality development of the industry.
-
Domestic pharmaceutical companies stormed the 100 billion anti-tumor drug market, and there is good news!
Time of Update: 2023-02-03
js?cdnversion='+~(-new Date()/36e5)];Recently, CT Tianqing Pharmaceutical's self-developed Class 1 new drug TQB2102 for injection has obtained the implied license of clinical trials and is intended to be used for the treatment of advanced malignant tumors.
-
The State Food and Drug Administration approved the marketing of the new Chinese medicine drug Qi Jiao Jingjing Granules
Time of Update: 2023-02-03
The drug has carried out multi-center, randomized, double-blind, marketed parallel controlled clinical trials of traditional Chinese medicines.
The drug has carried out multi-center, randomized, double-blind, marketed parallel controlled clinical trials of traditional Chinese medicines.
-
Announcement of the State Food and Drug Administration on the conversion of Lu Dang ginseng oral liquid to an over-the-counter drug
Time of Update: 2023-02-03
Other contents of the instructions other than those specified in the model leaflet for over-the-counter drugs shall be executed in accordance with the original approval documents.
Other contents of the instructions other than those specified in the model leaflet for over-the-counter drugs shall be executed in accordance with the original approval documents.
-
The State Food and Drug Administration revised the drug instructions for children's Baotaikang granules, Xinkeshu preparations, maple gastroenteric preparations, and spleen raising granules
Time of Update: 2023-02-03
According to the results of adverse drug reaction assessment, in order to further protect the safety of public medication, the State Medical Products Administration decided to uniformly revise the [adverse reactions], [contraindications] and [precautions] items in the drug instructions of Pediatric Baotaikang Granules, Xinkeshu Preparation, Maple Lotus Gastroenteric Health Preparation, and Awakening Spleen and Raising Children Granules.
-
Pharmaceutical companies are accelerating the evaluation of generic drugs, and some companies have ushered in a bumper harvest
Time of Update: 2023-02-03
Coincidentally, on December 29, Qianhong Pharmaceutical also announced that the company recently received the "Drug Supplement Application Approval Notice" on "dalteparin sodium injection" approved and issued by the State Food and Drug Administration, and approved the drug to pass the consistency evaluation of the quality and efficacy of generic drugs.
-
State Food and Drug Administration: Strengthen the supervision of the sale of new crown prevention and control drugs
Time of Update: 2023-02-03
On the 4th, the General Department of the State Food and Drug Administration issued the Notice on Strengthening the Quality Supervision of the Zero Sale of New Crown Prevention and Control Drugs, req
-
State Food and Drug Administration: China's domestic extracorporeal membrane oxygenation therapy (ECMO) products have been approved for marketing
Time of Update: 2023-02-03
According to the State Food and Drug Administration, according to the needs of epidemic prevention and control work, in order to ensure the treatment needs of severe patients with novel coronavirus p
-
The National Drug Supervision and Administration Work Conference was held in Beijing
Time of Update: 2023-02-03
On January 5, the National Drug Supervision and Administration Work Conference was held in Beijing. The meeting was guided by the thought of socialism with Chinese characteristics in the new era, dee
-
Traditional Chinese medicine still has opportunities for sector valuation improvement, optimistic about three major directions
Time of Update: 2023-02-03
js?cdnversion='+~(-new Date()/36e5)];In the future, with the overall support of national policies, there are still opportunities for the valuation of traditional Chinese medicine.
js?cdnversion='+~(-new Date()/36e5)];In the future, with the overall support of national policies, there are still opportunities for the valuation of traditional Chinese medicine.
-
Under the general trend of innovation, the good news of new drug research and development in the domestic drug market continues!
Time of Update: 2023-02-03
Kangtai Biotech announced on the evening of January 5 that the mumps and cheek combined live attenuated vaccine developed by Minhai Biotechnology, a wholly-owned subsidiary of the company, recently obtained the "Drug Clinical Trial Approval Notice" issued by the State Medical Products Administration, and after review, the drug met the relevant requirements of drug registration and agreed to conduct clinical trials.
-
Under the continuous improvement of the demand for manufacturing upgrading, cost reduction and efficiency improvement in the pharmaceutical industry, pharmaceutical machinery companies have set off a wave of fundraising and production expansion
Time of Update: 2023-02-03
Under the upgrading of pharmaceutical manufacturing, pharmaceutical machinery companies have set off a wave of fundraising and expansion It is understood that in recent years, in order to improve the layout of the whole industrial chain, Dongfulong has continued to increase independent research and development, and has won a large number of orders, which has promoted the continuous growth of performance.
-
Long-term opportunities for the innovative industry of traditional Chinese medicine have emerged! A large number of enterprises will benefit
Time of Update: 2023-02-03
Wellcome Pharmaceutical also said that it attaches great importance to the R&D and innovation of traditional Chinese medicine, and achieved operating income of 474 million yuan in the first three quarters of 2022, and net profit attributable to the parent of 94 million yuan, a year-on-year increase of 1.
-
The head pharmaceutical machine enterprises continue to increase investment in research and development, and move steadily forward on the road of product upgrading!
Time of Update: 2023-02-03
js?cdnversion='+~(-new Date()/36e5)];In recent years, with the rapid development of biological drugs and other industries, and the accelerated transformation and upgrading of the pharmaceutical industry under the new medical reform, the domestic pharmaceutical equipment industry has ushered in a new round of development opportunities, in this context, the head pharmaceutical machine enterprises represented by Chutian Science and Technology, Dongfulong, etc.
-
Recently, financing in the pharmaceutical field has been active, and many enterprises have reached 100 million yuan
Time of Update: 2023-02-03
On December 30, Xinkainuo Medical Company announced the completion of a financing of 100 million yuan, jointly invested by Zhangjiang Hi-Tech, Pudong Capital, Zhangjiang Haoheng and Suxin Venture Capital.
-
The market space of the drug molecular building block industry is broad, and domestic pharmaceutical companies have begun to enter one after another
Time of Update: 2023-02-03
js?cdnversion='+~(-new Date()/36e5)];Molecular building blocks are mainly used in drug discovery and the synthesis of target compounds in organic methodology, and are important fragments that make up drug molecules.
-
After 4 days of medical insurance negotiations, this drug failed due to high quotation!
Time of Update: 2023-02-03
Anticancer drugs and rare disease drugs are the focus of this round of negotiations According to the list previously released by the National Health Insurance Administration, 343 drugs passed the formal review this time, including 198 new varieties of drugs outside the list and 145 varieties of drugs renewed in the catalog.
-
A number of medical equipment companies are expected to increase their net profit by more than 100%! The industry market space is expected to continue to expand
Time of Update: 2023-02-03
According to CHOICE data, in the first three quarters of 2022, the 35 A-share listed companies in Shenwan's medical equipment industry achieved operating income of 53.
According to CHOICE data, in the first three quarters of 2022, the 35 A-share listed companies in Shenwan's medical equipment industry achieved operating income of 53.